Compare Amgen, Inc. (AMGN) vs Fox Corp Class A (FOXA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Fox Corp Class A — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Fox Corp Class A trades at $54.28 (market cap $21.54B). The key difference: Amgen, Inc. is far larger — about 9.1× Fox Corp Class A's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FOXA | |
|---|---|---|
Market Cap | $196.12B | $21.54B |
Sector | Health | Media |
52-Week High | $388.16 | $76.11 |
52-Week Low | $271.18 | $48.79 |
Enterprise Value | $241.41B | $25.51B |
Dividend Yield | 2.77% | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FOXA trades at $54.12, up 0.71% today, with a bearish technical signal despite recent earnings beats. The company reported strong 2025 results with revenue of $16.3B and net income of $2.26B, but faces headwinds from its $22B Roku acquisition. Analyst consensus remains positive with a $67.80 price target, though technical indicators show selling pressure near resistance at $55.
The outlook balances solid fundamentals against acquisition integration risks. FOXA's attractive valuation (P/E 14.24) and cash flow strength support upside potential, but investor sentiment is cautious due to leverage from the Roku deal. Near-term performance hinges on successful execution of streaming strategy amid industry consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
